Science 37 Holdings, Inc. - SNCE STOCK NEWS

Science 37, a leader in enhancing patient access to clinical trials, has been awarded Frost & Sullivan's 2024 Global Company of the Year Award for Decentralized Clinical Trials. This prestigious honor recognizes Science 37's visionary innovation, market-leading performance, and unmatched customer care in the industry.

The award solidifies Science 37's growing influence in the clinical trial sector, which is increasingly turning to decentralization to overcome recruitment, enrollment, and retention challenges. Frost & Sullivan selected Science 37 after a rigorous analytical process considering multiple nominees and evaluating Best Practices criteria across two dimensions.

David Coman, CEO of Science 37, expressed deep honor in receiving this recognition, emphasizing the company's commitment to transforming the clinical trial process for the benefit of both patients and sponsors.

Science 37, a leader in enhancing patient access to clinical trials, has unveiled its new 19,000-square-foot corporate headquarters in Morrisville, North Carolina, within Research Triangle Park. This state-of-the-art facility will serve as a centralized hub for all Science 37 operations, fostering cross-functional collaboration and integrated solution delivery. The move is expected to improve the company's ability to support clinical trial sponsors with greater consistency, speed, and quality in patient recruitment and study conduct.

CEO David Coman emphasized that the relocation not only enhances their operational capabilities but also symbolizes Science 37's commitment to the region and to helping sponsors improve their probability of success in clinical trials. This strategic move reflects the company's recent growth and continued dedication to advancing clinical research accessibility.

Science 37, a leader in enhancing patient access to clinical trials, has reported significant success in its partnership with a biopharmaceutical company focused on infectious disease prevention research. For a Phase 3 trial involving immunocompromised patients, Science 37 utilized its proprietary Virtual Site and Patient Recruitment solutions to achieve remarkable results:

- Recruited and enrolled 129 patients across 36 states in just 8 weeks
- Averaged 65 patient enrollments per month
- Successfully randomized and treated 42% of the trial cohort
- Achieved significant geographic, socio-economic, and cultural diversity among participants

This achievement highlights Science 37's capability to meet challenging clinical trial demands while enhancing patient access and care for vulnerable populations in a fully decentralized manner.

Science 37 has significantly enhanced patient recruitment and enrollment in over 20 clinical trials that were underperforming. Their proprietary Virtual Site and Patient Recruitment solutions facilitated the identification, recruitment, medical qualification, and enrollment of patients without geographic limitations. This intervention has been effective in Phase 2 through Phase 4 and Observational trials across various therapeutic areas, including Hematology, Hepatology, Infectious Diseases, CNS, Oncology, and Rare Diseases. The company's Patient Recruitment service is available both independently and in combination with their Virtual Site, Metasite™, to accelerate patient access and improve trial outcomes.

Science 37 announced it has surpassed enrollment goals for a Phase 2 clinical trial of a small molecule therapeutic for Cholestatic Pruritus, enrolling 21% of study participants using its Metasite™ and Patient Recruitment solutions.

Over a 20-month period from September 2022 to April 2024, Science 37 achieved 11 times the average enrollment speed of traditional research sites, enrolling an average of 1 patient per month.

This success highlights Science 37's ability to recruit patients from broader geographical areas, enhancing the efficiency of rare disease research.

These services are available to clinical research sponsors and CROs either as standalone offerings or integrated with their Virtual Site solutions.

Science 37 Holdings, a leader in patient access to clinical trials, announced that it exceeded enrollment goals in a Phase 2 clinical trial for EP547, a treatment for Cholestatic Pruritus in Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis. Over a 20-month period, Science 37 enrolled 21% of participants, achieving an enrollment rate of 1 patient per month, significantly faster than the 0.1 patients per month at traditional sites. This was made possible through their proprietary Metasite™ and Patient Recruitment solutions, which broaden the pool of qualified participants beyond local trial site areas.

Science 37 Holdings, Inc. announced the successful outcome of its recent FDA inspection for the Science 37 Metasite™ virtual site model, focusing on critical areas like data integrity, subject safety, and Principal Investigator oversight. The inspection, conducted between February 26 and March 6, 2024, resulted in no significant issues identified, showcasing Science 37’s commitment to regulatory compliance and quality research. This milestone underscores Science 37’s ability to provide high-quality, compliant data and accelerate clinical research.

Science 37 Holdings, Inc. has been awarded the 'Clinical Efficiency Innovation Award' in the 8th annual MedTech Breakthrough Awards program for its transformative patient recruitment solution. The company's AI-powered patient screening capabilities and nationwide medical licensure have revolutionized the conventional recruitment methods, resulting in improved patient experience, increased randomization rates, and better site satisfaction.

Science 37 Holdings, Inc. announced its partnership with a leading biotech company for a Phase 3 asthma clinical trial, achieving 22x faster enrollment compared to traditional methods. Science 37 contributed 28% of study participants over 15 months, enrolling an average of 44 patients monthly, while brick-and-mortar sites enrolled only 2. The company's innovative approach significantly reduced the study's time-to-target enrollment, showcasing its effectiveness in accelerating clinical research.